Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
7
self-reported 2–10 band
Founded
2021
5 years
Legal entities
1
ABR
Office countries
1
1 address
Funding rounds
None on record
Company type
Privately Held
self-reported
Legal entity
1 brand → 1 confirmed entity
FACIO BIOTHERAPIES PTY LTD
ABN63652512564
Legal entities
Show as table · Facio BioTherapies Pty Ltd: 1 registry entity
| FACIO BIOTHERAPIES PTY LTD | ABN 63652512564 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Facio Biotherapies Pty Limited (“FACIO”) was founded in 2023 in collaboration with the FSHD Global Research Foundation to focus solely on discovering and developing innovative diagnostic solutions and targeted therapies for Facioscapulohumeral Muscular Dystrophy (FSHD).
FACIO is a pre-clinical stage biotechnology company headquartered in Australia, with research collaborations in Melbourne, Sydney, Washington DC, and Seattle Washington.
FSHD Global Research Foundation is a patient-led, philanthropic foundation. Since its inception in 2008, the FOUNDATION has disbursed grants of >$20 million to enable discovery, diagnostic, biomarker and clinical research.
FSH muscular dystrophy (FSHD) is a highly complex muscle wasting disease causing progressive weakness that affects over one million people globally. The condition is caused by a toxic gain of function genetic alteration in a transcription factor (DUX4) that is normally silenced after embryonic development. Currently there are no approved treatments for FSHD and the condition suffers from lack of investment in basic and translational research.
FACIO's VISION is to transform the standard of care and to ultimately cure FSHD.
Our MISSION is to develop best-in-disease, targeted therapies that: 1) modify the toxic genes that cause FSHD, 2) are muscle tissue targeting 3) have disease modifying potential, 4) are safe and well tolerated and 5) are durable in mechanism of action.
FACIO is connecting with FSHD Patient Advocacy Groups in Australia and Globally to ensure we embed the patient voice and experience in co-designing solutions, and to access enablers of innovation. This connection informs our science and how we think about addressing unmet patient needs.
Under a strategic collaboration with FSHD Global Research Foundation, FACIO is committed to evaluating IP created by its research partners and to creating a commercialisation pathway for projects supported by the FOUNDATION.
Specialties
- biotechnology
- commercialisation
- market access
- genomics
- chemistry
- diagnostics
- discovery
- regeneration
- regulatory affairs
All 16 specialties
- Biotechnology
- neuromuscular disease
- biomarkers
- biopharmaceuticals
- nucleic acid therapies
- commercialisation
- scientific affairs
- discovery
- chemistry
- neurodegeneration
- regeneration
- muscle biology
- genomics
- diagnostics
- market access
- regulatory affairs
Related specialties
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | AU |
All codes: AU
Addresses
- AUSydney, NSWPrimary
Grid intelligence Members
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
3 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Names are withheld until a consented source exists.
FAQ
Which legal entity operates under Facio BioTherapies Pty Ltd?
One New South Wales entity on the ABR: FACIO BIOTHERAPIES PTY LTD (ABN 63 652 512 564), high confidence.
How many people work at Facio BioTherapies Pty Ltd?
7 counted staff profiles at January 2026, inside the self-reported 2–10 band.
Where does Facio BioTherapies Pty Ltd have offices?
One address on record, Australia only. Primary: Sydney, NSW.
Has Facio BioTherapies Pty Ltd raised funding?
None linked to this brand.
What does Facio BioTherapies Pty Ltd list as its specialties?
16 tags on the brand's own list, among them biotechnology, commercialisation and market access.
Which companies are listed alongside Facio BioTherapies Pty Ltd?
Four peer profiles on record: FSHD Global Research Foundation and BullionFX.